These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29734146)

  • 1. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y; Moriyama T; Itabashi M; Takei T; Nitta K
    Contrib Nephrol; 2018; 195():12-19. PubMed ID: 29734146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab and minimal change nephrotic syndrome: a therapeutic option.
    Takei T; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):641-647. PubMed ID: 21611755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
    Takei T; Itabashi M; Moriyama T; Kojima C; Shiohira S; Shimizu A; Tsuruta Y; Ochi A; Amemiya N; Mochizuki T; Uchida K; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2013 May; 28(5):1225-32. PubMed ID: 23239834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
    Iijima K; Sako M; Kamei K; Nozu K
    Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
    Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the response of frequently relapsing steroid-dependent minimal change nephrotic syndrome to rituximab therapy between childhood-onset and adult-onset disease.
    Iwabuchi Y; Miyabe Y; Makabe S; Nakano M; Manabe S; Karasawa K; Moriyama T; Nitta K
    Medicine (Baltimore); 2018 Oct; 97(42):e12704. PubMed ID: 30334956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.
    Gilbert RD; Hulse E; Rigden S
    Pediatr Nephrol; 2006 Nov; 21(11):1698-700. PubMed ID: 16932900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.
    Miyabe Y; Takei T; Iwabuchi Y; Moriyama T; Nitta K
    Clin Exp Nephrol; 2016 Feb; 20(1):103-10. PubMed ID: 26138356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.
    Sawara Y; Itabashi M; Kojima C; Tabata H; Kamei D; Kawanishi K; Moriyama T; Sugiura H; Tsukada M; Takei T; Ogawa T; Yoshida T; Arai J; Uchida K; Tsuchiya K; Nitta K
    Clin Nephrol; 2009 Jul; 72(1):69-72. PubMed ID: 19640390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
    Kronbichler A; Bruchfeld A
    Nephron Clin Pract; 2014; 128(3-4):277-82. PubMed ID: 25401966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations.
    François H; Daugas E; Bensman A; Ronco P
    Am J Kidney Dis; 2007 Jan; 49(1):158-61. PubMed ID: 17185157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
    Munyentwali H; Bouachi K; Audard V; Remy P; Lang P; Mojaat R; Deschênes G; Ronco PM; Plaisier EM; Dahan KY
    Kidney Int; 2013 Mar; 83(3):511-6. PubMed ID: 23325085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P; Bonanni A; Ghiggeri GM
    BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
    Gauckler P; Shin JI; Alberici F; Audard V; Bruchfeld A; Busch M; Cheung CK; Crnogorac M; Delbarba E; Eller K; Faguer S; Galesic K; Griffin S; Hrušková Z; Jeyabalan A; Karras A; King C; Kohli HS; Maas R; Mayer G; Moiseev S; Muto M; Odler B; Pepper RJ; Quintana LF; Radhakrishnan J; Ramachandran R; Salama AD; Segelmark M; Tesař V; Wetzels J; Willcocks L; Windpessl M; Zand L; Zonozi R; Kronbichler A;
    Autoimmun Rev; 2020 Nov; 19(11):102671. PubMed ID: 32942039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.
    Peters HP; van de Kar NC; Wetzels JF
    Neth J Med; 2008 Nov; 66(10):408-15. PubMed ID: 19011266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.
    Iwabuchi Y; Takei T; Moriyama T; Itabashi M; Nitta K
    Medicine (Baltimore); 2014 Dec; 93(29):e300. PubMed ID: 25546674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotic syndrome and rituximab: facts and perspectives.
    Haffner D; Fischer DC
    Pediatr Nephrol; 2009 Aug; 24(8):1433-8. PubMed ID: 19495800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.